# PARTNER

Source: https://onco.cc/trials/partner/  
OnCo record `partner` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding olaparib to this neoadjuvant chemotherapy schedule did not improve response or survival in germline-BRCA-wild-type TNBC.

## Summary

The registry lists NCT03150576 as recruiting, last updated 2022-11-14. Enrolment is 780 planned participants, an estimate. Interventions: Olaparib, Paclitaxel and Carboplatin. Primary measures include Stage 1 - Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.03.; Stage 2 - pCR rate and completion rate of Olaparib treatment as per protocol.. No results are posted in the registry; this does not exclude separate publications. The 2024 germline-BRCA-wild-type randomised cohort included 559 participants. Pathological complete response was 51% versus 52% (p=0.753); three-year event-free survival was 80% versus 79% (p>0.9), and overall survival was 90% versus 87.2% (p=0.8). The separate 2025 germline-BRCA-positive cohort reported no pCR improvement (64.1% versus 69.8%, p=0.59), but estimated three-year EFS of 96.4% versus 80.1% and OS of 100% versus 88.2% (both p=0.04). The authors state that the result needs confirmation in larger trials. This is not a positive result in the wild-type population.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: PARTNER trial; NCT03150576
- Tags: uk; breast; neoadjuvant
- Registry id: NCT03150576
- Phase: 2/3
- Setting: Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients With TNBC and/or gBRCA.
- Sponsor: Cambridge University Hospitals NHS Foundation Trust
- Result: Germline-BRCA-wild-type cohort (Nature 2024): no pCR, EFS or OS improvement. Separate germline-BRCA cohort (Nature Communications 2025): primary pCR endpoint not improved; three-year survival signal needs confirmation.

## Notes

- Registry facts (24 September 2026): randomised three-stage phase 2/3 (NCT03150576) of olaparib added to neoadjuvant paclitaxel and carboplatin in triple-negative or germline BRCA breast cancer, sponsored by Cambridge University Hospitals with AstraZeneca and Cancer Research UK; 780 patients estimated; stage 3 primary endpoint pathological complete response by central review; status recruiting; 30 UK sites from Ayr and Kilmarnock to Swansea, Cardiff, Cambridge, Oxford, University College London Hospital and the Royal Free.

## Sources

- Nature 2024 (DOI): https://doi.org/10.1038/s41586-024-07384-2
- University of Cambridge news release: https://www.cam.ac.uk/research/news/new-approach-to-treating-aggressive-breast-cancers-shows-significant-improvement-in-survival
- Be Part of Research record: https://bepartofresearch.nihr.ac.uk/trial-details/trial-detail?trialId=NCT03150576
- PARTNER wild-type primary paper: https://doi.org/10.1038/s41586-024-07384-2
- Separate germline-BRCA cohort: https://doi.org/10.1038/s41467-025-59151-0
- ClinicalTrials.gov NCT03150576: https://clinicaltrials.gov/study/NCT03150576

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Olaparib](https://onco.cc/drugs/olaparib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- institutions: [Addenbrooke's Hospital, Cambridge University Hospitals](https://onco.cc/institutions/addenbrookes-cambridge/), [Cancer Research UK Cambridge Centre / CRUK Cambridge Institute](https://onco.cc/institutions/cruk-cambridge-centre/)
- terms: [Germline BRCA mutation (gBRCA)](https://onco.cc/terms/gbrca-mutation/), [Pathologic complete response (pCR)](https://onco.cc/terms/pcr/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- trials: [BrighTNess](https://onco.cc/trials/brightness/), [KEYNOTE-522](https://onco.cc/trials/keynote-522/), [PHOENIX DDR/Anti-PD-L1](https://onco.cc/trials/phoenix/)
- people: [Jean Abraham](https://onco.cc/people/jean-abraham/)

---
JSON: https://onco.cc/api/v1/entities/partner.json